Nephro Care shares list at 90% premium on NSE SME platform

Nephro Care made a strong market debut on NSE SME platform with a 90% premium. The IPO garnered massive investor interest, oversubscribed by over 700 times. The company aims to establish a 100-bed multispeciality hospital in Kolkata using proceeds from the IPO. Nephro Care, led by Dr. Pratim Sengupta, focuses on comprehensive medical services for renal patients.

The shares of listed on the on Friday with a premium of 90%. The stock debuted at Rs 171 as against an offer price of Rs 90.

Ahead of the listing, the company's shares traded with a premium of Rs 230 in the unlisted market.

The , which was completely a fresh equity sale of 45.84 lakh shares generated massive response among investors with an overall subscription of over 700 times at close.

The Kolkata-based company plans to utilise a portion of the net proceeds from the IPO to set up a 100-bed multispeciality hospital called ‘’ at Madhyamgram in Kolkata. The remaining part of the proceeds will be utilised for general corporate purposes.

The hospital will be a unit of Nephro Care India and is proposed to include 100 inpatient beds, including a 30-bed Critical Care unit having ICU, HDU, RTU and NICU facilities.

Also Read:

Vivacity will offer treatment services in various disciplines such as cardiology, medical oncology, gastroenterology, gynecology and many others, including an advanced renal transplant unit in East India.

Nephro Care was founded in the year 2014 by , in Kolkata, with the objective of providing comprehensive medical services for renal patients. Dr Sengupta has over 20 years of active clinical experience, claimed the release saying that he has successfully performed more than 1,000 kidney transplants till now.

Nephro Care India operates on a multidimensional patient engagement framework comprising programs and facilities such as mukti, home dialysis, home care and diagnostics.

While Mukti takes care of the overall well-being of the patient to improve the quality of life through a blend of modern medicine and ancient yogic wisdom, home dialysis offers dialysis at the comfort of homes to CKD patients who are unable to visit the dialysis centres.

Meanwhile, home care services ensure clinical and lifestyle support beyond clinics to take care of all collateral medical needs of the patients.

The company posted a revenue of Rs 19.90 crore and earned a profit (PAT) of Rs 3.4 crore during the first nine months of FY 2023-24, compared to a revenue of Rs 17.09 crore, with a profit (PAT) of Rs 1.94 crore in FY23.

Source: Stocks-Markets-Economic Times

Останні публікації
Oklo target nearly doubled at Wedbush on AI-driven demand for nuclear energy
24.01.2025 - 18:00
Crypto markets lose steam after Trump's first policy move
24.01.2025 - 18:00
Combination of Google's TPU-DeepMind units may be worth $700 bn - DA Davidson
24.01.2025 - 18:00
British American Tobacco, Altria shares rise after menthol ban proposal dropped
24.01.2025 - 18:00
Morocco stocks higher at close of trade; Moroccan All Shares up 0.34%
24.01.2025 - 18:00
Commerzbank says no talks with UniCredit until specific proposal made
24.01.2025 - 18:00
Venture Global aims for $64 billion valuation at debut in test for energy IPOs
24.01.2025 - 18:00
Intuitive Machines stock surges on NASA contract award
24.01.2025 - 18:00
International Paper's $7.2 billion acquisition of DS Smith gets EU approval
24.01.2025 - 18:00
Short-term stock optimism soars among retail investors, AAII survey shows
24.01.2025 - 18:00
Venture Global shares likely to open up to 6% above IPO price
24.01.2025 - 18:00
Intuitive Surgical, American Express Stir Friday's Market Cap Stock Movers
24.01.2025 - 18:00
BMW joins Chinese EV makers in filing EU court challenge to tariffs
24.01.2025 - 18:00
Turkey stocks lower at close of trade; BIST 100 down 0.08%
24.01.2025 - 18:00
Diageo stock jumps on possible Guinness sale
24.01.2025 - 18:00

© Analytic DC. All Rights Reserved.

new
Аналіз ринку Як вплине завтра звіт NFP на курс долара США?